Active	Status	Sponsor type	Region	Phase	Filter
11 Active 5 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Isaacs, Claudine
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer	Active, not recruiting	2	70	US	tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201	Seagen Inc.	HER2 Positive Breast Cancer	07/24	10/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab	Active, not recruiting	2	174	US	Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma	Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium	Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer	10/24	07/27
PALAVY, NCT04841148: Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer	Recruiting	2	96	US	HCQ, Hydroxychloroquine sulfate, Plaquenil, Avelumab, MSB0010718C, Bavencio, Palbociclib, Ibrance	Abramson Cancer Center at Penn Medicine, Johns Hopkins University, Translational Breast Cancer Research Consortium, Pfizer, Breast Cancer Research Foundation	Breast Cancer	11/24	05/28
TALAVE, NCT03964532: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer	Active, not recruiting	1/2	24	US	Talazoparib, Talzenna, Avelumab, Bavencio	Georgetown University, Pfizer	Breast Cancer	12/24	12/24
NCT03854903: WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor	Active, not recruiting	1	19	US	Palbociclib, Ibrance, Bosutinib, Bosulif, Fulvestrant, Faslodex	Georgetown University, Pfizer	Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer	11/23	11/25
NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	Terminated	1	23	US	Niraparib, MK-4827, Carboplatin, Paraplatin	Georgetown University, Tesaro, Inc., Oregon Health and Science University	Solid Tumor, Adult, Homologous Recombination Deficiency	10/23	10/23